452 related articles for article (PubMed ID: 22560299)
1. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Curiel RV; Guzman NJ
Semin Arthritis Rheum; 2012 Oct; 42(2):166-78. PubMed ID: 22560299
[TBL] [Abstract][Full Text] [Related]
2. Management of gouty arthritis in patients with chronic kidney disease.
Abdellatif AA; Elkhalili N
Am J Ther; 2014; 21(6):523-34. PubMed ID: 22960848
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat: drug review and update.
Grewal HK; Martinez JR; Espinoza LR
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):747-58. PubMed ID: 24684266
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
5. Pegloticase for treatment of tophaceous polyarticular gout.
Seifried RM; Roberts J
Hawaii J Med Public Health; 2013 Jul; 72(7):220-3. PubMed ID: 23901393
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
7. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
8. Management of acute and chronic gouty arthritis: present state-of-the-art.
Schlesinger N
Drugs; 2004; 64(21):2399-416. PubMed ID: 15481999
[TBL] [Abstract][Full Text] [Related]
9. [Gout and other crystal-induced arthritides].
Manger B
Dtsch Med Wochenschr; 2012 Aug; 137(31-32):1579-81. PubMed ID: 22786675
[No Abstract] [Full Text] [Related]
10. Advances in pharmacotherapy for the treatment of gout.
Robinson PC; Dalbeth N
Expert Opin Pharmacother; 2015 Mar; 16(4):533-46. PubMed ID: 25547991
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics considerations for gout treatments.
Richette P; Frazier A; Bardin T
Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):949-57. PubMed ID: 24809930
[TBL] [Abstract][Full Text] [Related]
12. Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB; Neogi T
Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
[TBL] [Abstract][Full Text] [Related]
13. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.
Schlesinger N
Curr Rheumatol Rep; 2010 Apr; 12(2):130-4. PubMed ID: 20425022
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure.
Maekawa M; Tomida H; Aoki T; Hishida M; Morinaga T; Tamai H
Intern Med; 2014; 53(6):609-12. PubMed ID: 24633032
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
Schlesinger N; Lipsky PE
Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
[TBL] [Abstract][Full Text] [Related]
16. The Management of Gout in Renal Disease.
Estiverne C; Mount DB
Semin Nephrol; 2020 Nov; 40(6):600-613. PubMed ID: 33678314
[TBL] [Abstract][Full Text] [Related]
17. Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis.
Fanouriakis A; Karantanas A; Fragouli E; Repa A; Sidiropoulos P
Rheumatology (Oxford); 2014 Apr; 53(4):764-6. PubMed ID: 24185764
[No Abstract] [Full Text] [Related]
18. [New therapeutic options for gout].
Richette P; Ottaviani S; Bardin T
Presse Med; 2011 Sep; 40(9 Pt 1):844-9. PubMed ID: 21684104
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
20. Major unanswered questions in the clinical gout field.
Stamp LK
Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
